Humana (NYSE:HUM) Given New $260.00 Price Target at Truist Financial

Humana (NYSE:HUM) had its target price trimmed by Truist Financial from $400.00 to $260.00 in a report published on Friday morning, Benzinga reports. The firm currently has a hold rating on the insurance provider’s stock.

Several other equities analysts have also commented on HUM. Bank of America lowered Humana from a neutral rating to an underperform rating and cut their price target for the company from $376.00 to $247.00 in a research note on Wednesday, October 2nd. TD Cowen downgraded shares of Humana from a buy rating to a hold rating and cut their target price for the company from $402.00 to $261.00 in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Humana from $349.00 to $250.00 and set a hold rating for the company in a research report on Thursday, October 3rd. UBS Group cut their price objective on shares of Humana from $380.00 to $250.00 and set a neutral rating on the stock in a report on Friday, October 4th. Finally, Leerink Partnrs lowered Humana from a strong-buy rating to a hold rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Hold and a consensus target price of $315.33.

Humana Trading Up 2.6 %

Shares of HUM opened at $258.07 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The firm has a market capitalization of $31.10 billion, a price-to-earnings ratio of 16.07, a PEG ratio of 1.91 and a beta of 0.50. The company has a 50-day moving average of $324.76 and a 200 day moving average of $340.20. Humana has a 1-year low of $213.31 and a 1-year high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. Humana’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.94 earnings per share. On average, research analysts expect that Humana will post 16.06 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.37%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is 22.04%.

Hedge Funds Weigh In On Humana

A number of institutional investors have recently bought and sold shares of the business. CarsonAllaria Wealth Management Ltd. boosted its holdings in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the last quarter. Atwood & Palmer Inc. purchased a new stake in Humana in the third quarter valued at $29,000. Hantz Financial Services Inc. acquired a new stake in Humana during the 2nd quarter worth about $35,000. Family Firm Inc. purchased a new position in shares of Humana during the 2nd quarter valued at about $37,000. Finally, Hollencrest Capital Management acquired a new position in shares of Humana in the 2nd quarter valued at about $40,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.